Table 5.
Brentuximab vedotin combinations or monotherapy as first-line therapy in patients with advanced or predominantly advanced stage Hodgkin lymphoma (both approved and non-approved indications).
| Treatment | Patients (#) | Stage III/IV (%) | Age [Med (Range)] | PS ≥ 2(%) | RT (%) | ORR (CR), % | PFS (at n-yrs) | OS (at n-yrs) |
|---|---|---|---|---|---|---|---|---|
| ABVD × 6 (ECHELON-1) [17] | 102 | 100 | 66, (60–83) | 10 | NR | 83 (70) | 71.4% (2) | 17 deaths |
| BV-AVD × 6 (ECHELON-1) [17] | 84 | 100 | 68, (60–82) | 12 | NR | 86 (73) | 70.3% (2) | 15 deaths |
| BV × 2 + AVD × 6 + BV × 4 [86] | 48 | 81 | 69, (60–88) | 19 | 84(2) | 93(2) | ||
| B-CAP [87] | 49 | 95 | 66, (60–84) | 12 | 21 | 98 (65) | 74(1) | 93(1) |
| BV-DTIC × 12/3 ws [88] * | 22 * | 72 | 69, (62–88) | 32 | 5 | 100 (62) | median 17.9 mo § | nr §§ |
| BV-Bendamustine × 6 [88] * | 20 * | 75 | 75, (63–86) | 20 | 12 | 100(80) | nr † | nr † |
| BV-Bendamustine × 6 (HALO) [89] | 22 | 82 | 70, (62–79) | NR | NR | 87(87) | 5/15 pts | NR |
| BV alone [90] * | 27 * | 63 | 78, (64–92) | 22 | NR | 92 (73) | median 10.5 mo †† | median 11.8 mo †† |
| BV alone (BREVITY) [91] | 38 | 82 | 76, (59–90) | 50 | NR | 84(26) | median 7.4 mo | NR |
RT = radiotherapy; PFS = progression-free survival; OS = overall survival; NR = not reported; nr = not reached. * ≥60 years and ineligible or declined ABVD or BEACOPP: Median ejection fraction 60 (25–72), 60 (45–70), and 65 (49–74) for BV–DTIC, BV–Benda, and BV alone. § ≈49% at 2 years; §§ nr = not reached after a median follow-up of 21.6 months; † nr = not reached after a median follow-up of 10.8 months, PFS at 18 months ≈ 61%, Treatment-related mortality 10%; †† ~30% 18-month PFS and ~38% 18-month OS (derived from curves).